| Literature DB >> 29038470 |
Abstract
Recent advances in the HMP (human microbiome project) research have revealed profound implications of the human microbiome to our health and diseases. We postulated that there should be distinctive features associated with healthy and/or diseased microbiome networks. Following Occam's razor principle, we further hypothesized that triangle motifs or trios, arguably the simplest motif in a complex network of the human microbiome, should be sufficient to detect changes that occurred in the diseased microbiome. Here we test our hypothesis with six HMP datasets that cover five major human microbiome sites (gut, lung, oral, skin, and vaginal). The tests confirm our hypothesis and demonstrate that the trios involving the special nodes (e.g., most abundant OTU or MAO, and most dominant OTU or MDO, etc.) and interactions types (positive vs. negative) can be a powerful tool to differentiate between healthy and diseased microbiome samples. Our findings suggest that 12 kinds of trios (especially, dominantly inhibitive trio with mixed strategy, dominantly inhibitive trio with pure strategy, and fully facilitative strategy) may be utilized as in silico biomarkers for detecting disease-associated changes in the human microbiome, and may play an important role in personalized precision diagnosis of the human microbiome associated diseases.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29038470 PMCID: PMC5643543 DOI: 10.1038/s41598-017-12959-3
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
The 19 types of trios generated from a three-level classification scheme.
| The | The | The | ||||||||||||
| + - - Type-1 | ∑ | + + - Type-2 | ∑ | - | + | ∑ | - | + | + | + | ∑ | |||
|
|
|
|
| - | + | - | - | + | + | |||||
| - Type-3 | + Type-4 | - | - | - | + | |||||||||
| . | ||||||||||||||
| The | The | The | The | |||||||||||
| − SLM– | + SLM+ | ∑ | − | + | + | ∑ | − | + | + | + | ∑ | |||
| − | − | + | − | - | + | + | ||||||||
| − | − | - | + | |||||||||||
Datasets utilized to develop and test the TFP (trio finder program)
|
|
|
|
|
|---|---|---|---|
| Gut | IBD (Inflammatory Bowel Disease) | Crohn’s disease (CD, 18), Ulcerative colitis (UC: 38, 18), Healthy (18) | Agouridis |
| HIV | HIV Negative (20), ART (20), Non-ART (20) | McHardy | |
| Lung | Cystic Fibrosis (CF) | Exacerbation (25) | Fodor |
| Oral | Periodontitis | Healthy (17), Periodontitis with bleeding (PB) (22), Periodontitis without bleeding (PnB)(22) | Abusleme |
| Skin | Atopic Dermatitis (AD) | AD (36, 22) | Kong |
| Vaginal | Bacterial Vaginosis (BV) | BV (117) | Srinivasan |
.*The numbers parenthesized are the sample sizes, i.e., the number of individuals sampled in the original study or that used for constructing species correlation network. When there are two numbers (sample sizes) in the parentheses, the first number is the sample size of the original study, and the second number is the actual sample size we used to reconstruct the species correlation network in this article. The reason to use a different sample size from the original sample size is to avoid the influence of unbalanced treatments—the difference between treatments in the sample size is large enough to influence the results of network analysis. For example, in the case of IBD, the number of UC samples is 38, which is significantly more than the numbers of samples in the two other treatments (both are 18). To avoid the side effect of unbalanced treatments, 18 samples were drawn out of 38 samples and the sampling process was repeated for 50 times. From each sampling process, a network was reconstructed and the network properties including the numbers of trios were computed. The averages from the 50 sampling operations were taken as the final result for the sampled treatment. Two treatments, i.e., UC in IBD case, AD in Skin case were sampled to deal with the issue of unbalanced treatments.
The number of various trios in the class of “Trios without MAO handle” in the SIN.
| Microbiomes & Associated Disease Treatments | Trios with MAO | Trios without MAO | |||||||||||||
| + - - Type-1 | ∑ | + + - Type−2 | ∑ | Type-3 − | Type-4 + | ∑ | − | + | + | + | ∑ | ||||
|
|
|
|
| – | + | − | − | + | + | ||||||
| – | + | − | − | − | + | ||||||||||
|
| HIV-Negative | 36 | 14 | 50 | 0 | 0 | 0 | 0 | 86 | 136 | 0 | 365 | 0 | 2127549 | 2127914 |
| HIV-ART | 11 | 22 | 33 | 0 | 0 | 0 | 0 | 4 | 37 | 0 | 125 | 0 | 1683975 | 1684100 | |
| HIV-NonART | 3 | 0 | 3 | 0 | 0 | 0 | 0 | 110 | 113 | 0 | 43 | 0 | 1876511 | 1876554 | |
| IBD-Healthy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 278775 | 278775 | |
| IBD-CD | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 | 0 | 0 | 0 | 86738 | 86738 | |
| IBD-UC | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 34 | 35 | 0 | 11 | 0 | 280215 | 280226 | |
|
| End of treatment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 562 | 562 |
| Exacerbation | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1055 | 1055 | |
|
| Healthy | 0 | 21 | 21 | 0 | 0 | 0 | 0 | 0 | 21 | 0 | 27 | 0 | 42155 | 42182 |
| PB | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 9783 | 9786 | |
| PnB | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11607 | 11607 | |
|
| Healthy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AD | 0 | 30 | 30 | 0 | 0 | 0 | 0 | 0 | 30 | 0 | 0 | 0 | 65 | 65 | |
|
| Healthy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 5327 | 5328 |
| BV | 6 | 17 | 23 | 0 | 0 | 0 | 0 | 2 | 25 | 0 | 39 | 0 | 428 | 467 | |
The number of various trios in the class of “Trios with MAO handle” in the SIN.
| Microbiomes & Associated Disease Treatments | Single-Link MAO | Double-Link MAO | Triple-Link MAO | ||||||||||
| - | + | ∑ | - | + | + | ∑ | - | + | + | + | ∑ | ||
| - | - | + | - | - | + | + | |||||||
| - | - | - | + | ||||||||||
| Gut | HIV-Negative | 1029 | 311 | 1340 | 207 | 123 | 286 | 616 | 8 | 37 | 76 | 239 | 360 |
| HIV-ART | 434 | 21 | 455 | 171 | 17 | 1 | 189 | 24 | 13 | 3 | 1 | 41 | |
| HIV-NonART | 1 | 1381 | 1382 | 0 | 2 | 260 | 262 | 0 | 0 | 2 | 240 | 242 | |
| IBD-Healthy | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| IBD-CD | 0 | 25 | 25 | 0 | 0 | 4 | 4 | 0 | 0 | 0 | 1 | 1 | |
| IBD-UC | 8 | 633 | 641 | 0 | 1 | 123 | 124 | 0 | 0 | 1 | 71 | 72 | |
| Lung | End of treatment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exacerbation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Oral | Healthy | 485 | 0 | 485 | 192 | 0 | 0 | 192 | 27 | 0 | 0 | 0 | 27 |
| PB | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| PnB | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Skin | Healthy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| AD | 2 | 0 | 2 | 10 | 0 | 0 | 10 | 53 | 0 | 0 | 0 | 53 | |
| Vaginal | Healthy | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| BV | 60 | 24 | 84 | 31 | 14 | 3 | 48 | 14 | 6 | 1 | 0 | 21 | |
The RDHT (ratio of disease to healthy trios) of category-specific total trios in the human microbiome computed from Tables 3 & 4.
| Site |
| Trios with MAO | Trios without MAO | Single link with MAO | Double link with MAO | Triple link with MAO |
|---|---|---|---|---|---|---|
| Gut | HIV-ART/Negative | 0.27 | 0.79 | 0.34 | 0.31 | 0.11 |
| HIV-NonART/Negative | 0.83 | 0.88 | 1.03 | 0.43 | 0.67 | |
| IBD-CD/IBD-Healthy | 2.50 | 0.31 | 25.00 | Infinite | Infinite | |
| IBD-UC/IBD-Healthy | 17.50 | 1.01 | 641.00 | Infinite | Infinite | |
| Lung | Exacerbation/Treatment | Infinite | 1.88 | NA | NA | NA |
| Oral | PB/Healthy | 0.00 | 0.23 | 0.00 | 0.00 | 0.00 |
| PnB/Healthy | 0.00 | 0.28 | 0.00 | 0.00 | 0.00 | |
| Skin | AD/Healthy | Infinite | Infinite | Infinite | Infinite | Infinite |
| Vaginal | BV/Healthy | Infinite | 0.09 | 84.00 | Infinite | Infinite |
The RDHT (ratio of disease to healthy trios) of Type-1, 2, 3, 4 trios (i.e., Trios with MAO but no MAO handle) in the human microbiome computed from Table 3.
| Site |
| Type-1 | Type-2 | Type-3 | Type-4 | ||
|---|---|---|---|---|---|---|---|
| Type-1A | Type-1B | Type-2A | Type-2B | ||||
| Gut | HIV-ART/Negative | 0.31 | 1.57 | NA | NA | NA | 0.05 |
| HIV-NonART/Negative | 0.08 | 0.00 | NA | NA | NA | 1.28 | |
| IBD-CD/IBD-Healthy | Infinite | NA | NA | NA | NA | 2.50 | |
| IBD-UC/IBD-Healthy | Infinite | NA | NA | NA | NA | 17.00 | |
| Lung | Exacerbation/Treatment | Infinite | NA | NA | NA | NA | NA |
| Oral | PB/Healthy | NA | 0.00 | NA | NA | NA | NA |
| PnB/Healthy | NA | 0.00 | NA | NA | NA | NA | |
| Skin | AD/Healthy | NA | Infinite | NA | NA | NA | NA |
| Vaginal | BV/Healthy | Infinite | Infinite | NA | NA | NA | Infinite |